Akebia Therapeutics, Inc.
(NASDAQ : AKBA)

( )
AKBA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.03%296.881.4%$601.32m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
-0.78%67.101.0%$366.91m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%372.162.6%$302.06m
VRTXVertex Pharmaceuticals, Inc.
0.25%220.551.9%$275.13m
CLVSClovis Oncology, Inc.
1.64%13.6514.7%$245.81m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-1.32%67.3211.4%$205.58m
ALXNAlexion Pharmaceuticals, Inc.
0.81%113.382.0%$204.43m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
28.14%128.7414.6%$149.78m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BLUEbluebird bio, Inc.
-3.36%84.0514.2%$136.75m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.